Symphony Vida

Rockville, United States Acquired By Mateon Therapeutics
Therapeutics for cancer and eye diseases are developed.

About Symphony Vida

Symphony Vida is a Healthcare company based in Rockville (United States), and was acquired by Mateon Therapeutics in July 2009. Therapeutics for cancer and eye diseases are developed. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.

Company details

Therapeutics targeting cancer and neovascular eye diseases are developed by Symphony Vida, a biotechnology firm located in Rockville, United States. Operations center on advancing treatments for multiple cancer types and ocular conditions. A collaboration with Oxigene has been pursued to support drug development efforts in oncology and ophthalmology, with activities conducted primarily in the pharmaceutical sector.

Operational Areas
Key Metrics

Investors in Symphony Vida

Symphony Vida has secured backing from 1 investor. Prominent investors backing the company include Mateon Therapeutics.

All
InvestorDescriptionFounded YearDomainLocation
Vascular targeted therapies are developed for rare diseases and cancers.
1996mateon.comSan Francisco, United States
Premium access

Investor details for Symphony Vida

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Competitors of Symphony Vida

Symphony Vida has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
c4therapeutics.com2016Cambridge, United States$223M121
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
erasca.com2018San Diego, United States$300M120
Small molecule therapeutics for cancer treatment are developed.
miragen.com2007Boulder, United States$111.29M92
MicroRNA-based therapeutics are developed for treating multiple diseases.
Premium access

Detailed competitors of Symphony Vida

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Oncology

3 companies that operate in the same segment as Symphony Vida (Oncology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Symphony Vida

Symphony Vida is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.

Therapeutics targeting cancer and neovascular eye diseases are developed by Symphony Vida, a biotechnology firm located in Rockville, United States. Operations center on advancing treatments for multiple cancer types and ocular conditions. A collaboration with Oxigene has been pursued to support drug development efforts in oncology and ophthalmology, with activities conducted primarily in the pharmaceutical sector.

Symphony Vida's top competitors include C4 Therapeutics, Erasca and MiRagen.

Symphony Vida has 1 investor. Key investors include Mateon Therapeutics.

Yes. Symphony Vida was acquired by Mateon Therapeutics in July 2009.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available